NCT03826901 - Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions

Atopic Dermatitis

Interventions

DRUG

delgocitinib

Cream for topical application

Trial Locations (16)

LEO Pharma investigational site, Birmingham

LEO Pharma investigational site, Indianapolis

LEO Pharma investigational site, Ypsilanti

LEO Pharma investigational site, Tulsa

LEO Pharma investigational site, San Antonio

LEO Pharma investigational site, Centennial

LEO Pharma investigational site, Phoenix

LEO Pharma investigational site, Los Angeles

LEO Pharma investigational site, Irvine

LEO Pharma investigational site, Fountain Valley

LEO Pharma investigational site, Medford

LEO Pharma investigational site, New Haven

LEO Pharma investigational site, Red Deer

LEO Pharma investigational site, Hamilton

LEO Pharma investigational site, Montreal

LEO Pharma investigational site, Montreal